Sage Therapeutics (NASDAQ: SAGE) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Valuation and Earnings

This table compares Sage Therapeutics and Intellia Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sage Therapeutics N/A N/A -$222.35 million ($6.05) -10.53
Intellia Therapeutics $22.63 million 47.47 -$45.44 million ($1.34) -22.20

Intellia Therapeutics has higher revenue and earnings than Sage Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sage Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Sage Therapeutics and Intellia Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sage Therapeutics 0 2 10 1 2.92
Intellia Therapeutics 0 3 4 0 2.57

Sage Therapeutics presently has a consensus price target of $86.77, indicating a potential upside of 36.24%. Intellia Therapeutics has a consensus price target of $26.80, indicating a potential downside of 9.92%. Given Sage Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Sage Therapeutics is more favorable than Intellia Therapeutics.

Profitability

This table compares Sage Therapeutics and Intellia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sage Therapeutics N/A -64.86% -59.43%
Intellia Therapeutics -204.48% -22.70% -16.17%

Insider & Institutional Ownership

46.5% of Intellia Therapeutics shares are held by institutional investors. 6.1% of Sage Therapeutics shares are held by company insiders. Comparatively, 12.8% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Intellia Therapeutics beats Sage Therapeutics on 7 of the 13 factors compared between the two stocks.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.